BioWorld

Aug. 24, 2006

Ablynx €40M Round Notable Among European Financings

In one of the largest European private placements conducted this year, Ablynx NV raised €40 million (US$51.2 million) in a Series C round to drive more of its programs into preclinical and clinical development. (BioWorld Today) Read More

Theravance's Phase III Data: Non-Inferior To Vancomycin

Debate Over Whether New Stem Cell Science Will Change Policy

Kemia Adds $31M In Series C, Reports Positive Phase I Data

Theratechnologies SPA Aligns Second TH9507 Pivotal Study

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...